- Home
- JOF vs VNDA Comparison
JOF vs VNDA Comparison
Compare JOF & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JOF | VNDA |
|---|---|---|
| Founded | 1990 | 2002 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.6M | 301.1M |
| IPO Year | 1996 | 2005 |
Fundamental Metrics
Financial Performance| Metric | JOF | VNDA |
|---|---|---|
| Price | $12.47 | $4.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 63.8K | ★ 778.6K |
| Earning Date | 01-01-0001 | 10-28-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | N/A | $35.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $9.96 | $4.27 |
| 52 Week High | $12.85 | $9.91 |
Technical Indicators
Market Signals| Indicator | JOF | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 48.24 | 33.10 |
| Support Level | $12.15 | $4.45 |
| Resistance Level | $12.76 | $5.37 |
| Average True Range (ATR) | 0.17 | 0.17 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 26.60 | 20.92 |
Price Performance
Historical ComparisonAbout JOF Japan Smaller Capitalization Fund Inc
Japan Smaller Capitalization Fund Inc is a closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.